January 29, 2008 11:48 ET


NANTES, FRANCE and KUMAMOTO, JAPAN--(Marketwire - January 29, 2008) - VIVALIS AND KAKETSUKEN EXTEND THEIR COLLABORATION IN THE TESTING OF VIVALIS EBx® CELLS FOR THE PRODUCTION OF HUMAN AND VETERINARY VIRAL VACCINE. VIVALIS and THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE (KAKETSUKEN) announced today that they have extended the research licence to 2 new viruses, one in the field of human disease, the other in the veterinary field.

Vivalis has already granted Kaketsuken rights to the EBx® cell lines (avian embryonic derived stem cell lines) to evaluate Vivalis EBx® platform for the production of Kaketsuken's human and animal vaccines. Following this amendement, Kaketsuken's will have the right to test an aggregate of 7 viruses both in human and veterinary fields.

"Vivalis is pleased to extent the agreement with Kaketsuken and to support Kaketsuken's R&D efforts for the development of human and veterinary vaccines. This is a strong demonstration that Kaketsuken, which weights more than 25% of the Japan vaccine market, is convinced of the interest of Vivalis technology for several of its vaccines. Furthermore, it is a new proof that the EBx® cell line is not limited to few applications, but can be applicable to a very large spectrum of vaccines", said Franck Grimaud, Vivalis' CEO.

Dr. Akira Tashiro, Kaketsuken's Executive Managing Director, stated "Kaketsuken is very optimistic about the potential of Vivalis EBx® cell technology to effectively and efficiently replicate various human and veterinary viruses".

Terms of the agreement were not disclosed.



Vivalis (Euronext: VLS) is a biopharmaceutical company specialised in vaccines and in viral diseases. VIVALIS' know-how and proprietary technologies are commercially exploited in three main areas:

- Vaccine development and manufacturing. VIVALIS grants research & commercial licences to its proprietary EBx® embryonic stem cell lines to pharmaceutical and biotechnology companies active in the viral vaccine business.

- Recombinant therapeutic protein and monoclonal antibody expression systems development. VIVALIS partners with pharmaceutical and biotechnology companies in this area, to which it licences its proprietary EBx® embryonic stem cell lines to manufacture recombinant therapeutic proteins.

- The build-up of a proprietary portfolio of vaccines and anti- viral molecules.

Based in Nantes (France), Vivalis was created in 1999 by Group GRIMAUD (1350 employees), the n degrees2 group worldwide in avian genetic breeding. Vivalis has established several partnerships with companies that are worldwide leaders in their respective fields, including Sanofi Pasteur, GlaxoSmithKline, Novartis Vaccines, Merial and SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES cluster.

Eurolist Paris - Sector C - FR0004056851

Reuters: VLS.PA - Bloomberg: VLS FP

Investors Relation :


Franck Grimaud, C.E.O

Email :


Financial Communication Agency

Steve Grobet / Emmanuel Huynh

Tel. : +33 (0) 1 44 71 94 91

Email :


KAKETSUKEN is a Juridical Foundation which researches, develops, manufactures and supplies biological products such as vaccines for humans and animals, and blood plasma derivatives. Based in Kumamoto, Japan, the foundation has pursued the preventive medicine fields of microbiology, immunology and serology, towards the improvement of health and hygiene, and is a leading company in the fields of human vaccines, animal vaccines, and blood plasma derivatives respectively in Japan. In the field of human vaccines, Kaketsuken is currently manufacturing more than 10 kinds of vaccines for humans, such as Influenza vaccine, DTaP vaccine, recombinant Hepatitis B vaccine and Hepatitis A vaccine. Kaketsuken is also developing a therapeutic monoclonal antibody for HIV, a cell-cultured Japanese encephalitis vaccine and Influenza vaccine.

This information is provided by HUGIN

Contact Information

  • For further information please contact:
    Corporate Administration Division
    Kazuhiro Hamaji
    Tel : +81 96 344 1211
    Email Contact